Wells Fargo Raises Alnylam (ALNY) Revenue Estimates for Amvuttra Despite Projected Margin Compression [Yahoo! Finance]
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Yahoo! Finance
on Alnylam Pharmaceuticals, lowering the price target to $376 from $479 while maintaining an Equal Weight rating. While the firm increased its 2026 revenue estimates for Amvuttra by 6%, it expressed concern over rising costs. Specifically, the firm expects R&D expenses to climb to ~30% of total revenue between 2026 and 2030. This reinvestment is projected to compress operating margins to roughly 30%. On the same day, RBC Capital reduced its price target for Alnylam to $465 from $500 while maintaining an Outperform rating. This adjustment followed a meeting with the company's management team to discuss the 2026 net product revenue outlook. Management addressed recent performance for Amvuttra, explaining that a soft November resulted from a few one-off factors, which were followed by an impressive December. jason-briscoe-Gw_sFen8VhU-unsplash Earlier on January 12, Needham increased its price target for Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) from $520 to $529 with a Buy rating
Show less
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- Alnylam Pharmaceuticals (ALNY) Valuation Check After Recent Share Price Weakness [Yahoo! Finance]Yahoo! Finance
- Analyst Views Diverge as Alnylam Pharmaceuticals, Inc. (ALNY) Targets $5.1B Revenue and Long-Term Growth [Yahoo! Finance]Yahoo! Finance
- Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by analysts at Morgan Stanley from $495.00 to $408.00. They now have an "equal weight" rating on the stock.MarketBeat
- Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by analysts at HC Wainwright from $570.00 to $510.00. They now have a "buy" rating on the stock.MarketBeat
- Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by analysts at Bank of America Corporation from $529.00 to $462.00. They now have a "buy" rating on the stock.MarketBeat
ALNY
Earnings
- 10/30/25 - Beat
ALNY
Sec Filings
- 1/14/26 - Form 4
- 1/14/26 - Form 4
- 1/14/26 - Form 4
- ALNY's page on the SEC website